OF

Orthofix Medical Inc.

OFIXHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$822.3M
+2.9% YoY
Net Income
-$92.2M
+26.8% YoY
EBITDA
$9.9M
+154.3% YoY
Free Cash Flow
$4.1M

Scan Results

Daily timeframe
1 recent day hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Aug 25 RSI OversoldRSI 21.8, below 30, stock may be oversold
Aug 24 RSI OversoldRSI 22.6, below 30, stock may be oversold
About Orthofix Medical Inc.

Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. At a $375.5M market cap, Orthofix Medical Inc. ranks as a small-cap company within healthcare. It operates through two segments, Global Spine and Global Limb Reconstruction.

Where OFIX stands vs its 150-day and 200-day moving averages

As of the August 25, 2026 close, OFIX finished 15.68% below its 150-day moving average ($11.61) and 21.93% below its 200-day moving average ($12.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is OFIX overbought or oversold?

At the August 25, 2026 close, OFIX's RSI(14) was 21.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$375.5M
Fwd P/E25.11
EPS$-1.52
Beta0.65
52W Change-36.4%
ROE-13.9%
Analysis

The company holds $103.8M in cash, though total debt stands at $261.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $4.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -13.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $460.7M (2022) to $822.3M (2025), reflecting a 78% increase over the period.

OFIX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Orthofix Medical Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms